Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation

Circulation Research

Volumn 108, Issue 3, 2011, Pages 344-352

  Kleinbongard, Petra ^a   Böse, Dirk ^a   Baars, Theodor ^a   Möhlenkamp, Stefan ^a   Konorza, Thomas ^a   Schöner, Sandra ^a   Elter Schulz, Miriam ^a   Eggebrecht, Holger ^a   Degen, Hubertus ^b   Haude, Michael ^b   Levkau, Bodo ^a   Schulz, Rainer ^a   Erbel, Raimund ^a   Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Lukaskrankenhaus GmbH   (Germany)

Author keywords

coronary disease; ischemia; reperfusion; vasoconstriction; vasodilation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADRENALIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITROPRUSSIDE SODIUM; NORADRENALIN; POTASSIUM CHLORIDE; SEROTONIN; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ADRENALIN BLOOD LEVEL; ADULT; AGED; ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CATECHOLAMINE RELEASE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY CONSTRICTION; CORONARY STENT; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MESENTERIC ARTERY; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RAT; SAPHENOUS VEIN; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE;

ADENOSINE; AGED; ANIMALS; CORONARY ARTERY BYPASS; ENDOTHELINS; FEMALE; HUMANS; MALE; MESENTERIC ARTERIES; MIDDLE AGED; MODELS, ANIMAL; NITROPRUSSIDE; RATS; RATS, INBRED LEW; SAPHENOUS VEIN; SEROTONIN; STENTS; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION; VASODILATOR AGENTS; VERAPAMIL;

EID: 79751535376     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.235713     Document Type: Article

References (54)

1. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R. Postconditioning and protection from reperfusion injury: where do we stand? Cardiovasc Res. 2010;87:406-423.
2. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54: 1496-1508.
3. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol. 2010;55:1649-1660.
4. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JAC. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772. (Pubitemid 28135339)
5. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001;22:729-739. (Pubitemid 32625230)
6. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schomig A, Kastrati A. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55: 2383-2389.
7. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117:3152-3156.
8. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996;39: 113-118.
9. Sdringola S, Assali AR, Ghani M, Moustapha A, Achour H, Yusuf SW, Fujise K, Rosales O, Schroth GW, Anderson HV, Smalling RW. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 2001;54: 318-324.
10. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, Gibson CM. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14:299-302. (Pubitemid 34651235)
11. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation. 2009;120:1822-1836.
12. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sütsch G, Roffi M, Neidhart M, Eberli FR, Tanner FC, Gobbi S, von Eckardstein A, Lüscher TL. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction. Locally increased interleukin-6 and serum amyloid A but decreased c-reactive protein. Circulation. 2005;111: 1355-1361. (Pubitemid 40396800)
13. Leineweber K, Bose D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol. 2006; 47:981-986.
14. Boese D, Leineweber K, Konorza T, Zahn A, Brocker-Preuss M, Mann K, Haude M, Erbel R, Heusch G. Release of TNF-a during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. Am J Physiol Heart Circ Physiol. 2007; 292:H2295-H2299. (Pubitemid 47084610)
15. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932-936.
16. Chester AH, Allen SP, Tadjkarimi S, Yacoub MH. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation. 1993;87:874-880. (Pubitemid 23070819)
17. Prentice DJ, Payne SL, Hourani SM. Activation of two sites by adenosine receptor agonists to cause relaxation in rat isolated mesenteric artery. Br J Pharmacol. 1997;122:1509-1515. (Pubitemid 27503946)
18. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999;372:49-56. (Pubitemid 29229863)
19. Sato A, Terata K, Miura H, Toyama K, Loberiza FR Jr, Hatoum OA, Saito T, Sakuma I, Gutterman DD. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol. 2005;288:H1633-H1640. (Pubitemid 40417986)
20. Birch J, Brown E, Calnan C, Jessup CL, Jessup R, Wayne M. Studies in the guinea-pig with ICI 185,282: a thromboxane A2 receptor antagonist. J Pharm Pharmacol. 1988;40:706-710.
21. Nishimura Y. Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats. Br J Pharmacol. 1996;117:1325-1333. (Pubitemid 26105358)
22. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000;1483:285-293. (Pubitemid 30029060)
23. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005;26:2493-2519. (Pubitemid 41679359)
24. Rubanyi GM, Frye RL, Holmes DR, Vanhoutte PM. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol. 1987;9:1243-1249. (Pubitemid 17083521)
25. Golino P, Piscione F, Benedict CR, Anderson HV, Cappelli-Bigazzi M, Indolfi C, Condorelli M, Chiariello M, Willerson JT. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994;330: 523-528. (Pubitemid 24058954)
26. Leosco D, Fineschi M, Pierli C, Fiaschi A, Ferrara N, Bianco S, Longobardi G, Pisani E, Bravi A, Rengo F. Intracoronary serotonin release after high-pressure coronary stenting. Am J Cardiol. 1999;84: 1317-1322.
27. Mautner SL, Mautner GC, Hunsberger SA, Roberts WC. Comparison of composition of atherosclerotic plaques in saphenous veins used as aorto-coronary bypass conduits with plaques in native coronary arteries in the same men. Am J Cardiol. 1992;70:1380-1387.
28. Silva JA, White CJ, Collins TJ, Ramee SR. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. Am Heart J. 1998;136:156-163. (Pubitemid 28317881)
29. Pregowski J, Tyczynski P, Mintz GS, Kim SW, Witkowski A, Waksman R, Pichard A, Satler L, Kent K, Kalinczuk L, Bieganski S, Ohlmann P, Maehara A, Weissman NJ. Comparison of ruptured plaques in native coronary arteries and in saphenous vein grafts: an intravascular ultrasound study. Am J Cardiol. 2006;97:593-597. (Pubitemid 43255021)
30. Boese D, von Birgelen C, Zhou XY, Schmermund A, Philipp S, Sack S, Konorza T, Mohlenkamp S, Leineweber K, Kleinbongard P, Wijns W, Heusch G, Erbel R. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. Basic Res Cardiol. 2008;103:587-597.
31. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, De Vita M, Rebuzzi AG, Lüscher TF, Crea F. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J. 2006;27:1793-1798. (Pubitemid 44297383)
32. Adlbrecht C, Bonderman D, Plass C, Jakowitsch J, Beran G, Sperker W, Siostrzonek P, Glogar D, Maurer G, Lang IM. Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost. 2007;97:642-649. (Pubitemid 46592943)
33. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyöngyösi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 2002; 99:2794-2800. (Pubitemid 34525367)
34. Brambilla M, Camera M, Colnago D, Marenzi G, De MM, Giesen PL, Balduini A, Veglia F, Gertow K, Biglioli P, Tremoli E. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol. 2008;28:947-953. (Pubitemid 351544112)
35. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol. 2000;165:1605-1611. (Pubitemid 30604598)
36. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prosta-glandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104: 921-927. (Pubitemid 32778044)
37. Frisbee JC, Goodwill AG, Stapleton PA, Frisbee SJ, d'Audiffret AC. Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol Genomics. 2010;42:331-341.
38. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and athero-thrombotic disease. J Am Coll Cardiol. 2005;46:986-993.
39. Kleinbongard P, Heusch G, Schulz R. TNFa in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Therap. 2010; 127:295-314.
40. Zhang C, Xu X, Potter BJ, Wang W, Kuo L, Michael L, Bagby GJ, Chilian WM. TNF-a contributes to endothelial dysfunciton in ischemia/ reperfusion injury. Arterioscler Thromb Vasc Biol. 2006;26:475-480.
41. Gao X, Xu X, Belmadani S, Park Y, Tang Z, Feldman AM, Chilian WM, Zhang C. TNF-alpha contributes to endothelial dysfunction by upregu-lating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2007;27:1269-1275. (Pubitemid 46809414)
42. Zhang C, Wu J, Xu X, Potter BJ, Gao X. Direct relationship between levels of TNF-alpha expression and endothelial dysfunction in reperfusion injury. Basic Res Cardiol. 2010;105:453-464.
43. Fujita M, Minamino T, Sanada S, Asanuma H, Hirata A, Ogita H, Okada K, Tsukamoto O, Takashima S, Tomoike H, Node K, Hori K, Kitakaze M. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfued canine hearts. J Mol Cell Cardiol. 2004;37: 1219-1223. (Pubitemid 39575167)
44. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Mario CD, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008; 29:2909-2945.
45. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Kolh P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, Kearney P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel de la Riviere A, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501-2555.
46. Heusch G. Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve. Basic Res Cardiol. 2010;105:1-5.
47. Desmet W, Bogaert J, Bubois C, Sinnaeve P, Adriaenssens T, Ganame J, Dymarkowski S, Janssens S, Belmans A, van de Werf F. High dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2010; 31:766.
48. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358-1361. (Pubitemid 40719869)
49. Airoldi F, Briguori C, Cianflone D, Cosgrave J, Stankovic G, Godino C, Carlino M, Chieffo A, Montorfano M, Mussardo M, Michev I, Colombo A, Maseri A. Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside. Am J Cardiol. 2007;99: 916-920. (Pubitemid 46486727)
50. Zoghbi GJ, Goyal M, Hage F, Meyers RP, Papapietro SE, Brott BC, Misra VK, Iskandrian AE, Hillegass WB. Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions. J Invasive Cardiol. 2009;21:34-39.
51. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444-451. (Pubitemid 35424121)
52. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, Sutton A, de Belder MA. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278-1284. (Pubitemid 44298880)
53. Heusch G. Myocardial stunning: a role for calcium antagonists during ischaemia? Cardiovasc Res. 1992;26:14-19.
54. Campbell CA, Kloner RA, Alker KJ, Braunwald E. Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. J Am Coll Cardiol. 1986;8:1169-1174. (Pubitemid 16009105)